 |
|
Lung Cancer Trial Results
1. New Targeted Fluorescent-Imaging Compound Allows Researchers to Detect Viable Cancer Cells in Mice
(Posted: 12/08/2008) - Researchers have developed a new type of imaging compound that allows them to visualize viable breast cancer cells that have spread to the lungs in mice. The compound binds to a protein called HER2, which is found on the surface of some breast cancer cells, and it glows, or fluoresces, only when taken inside living cells. This method of targeting and activation allowed researchers to detect specific types of live cancer cells in a mouse model of breast cancer.
2. No Survival Benefit from Adjuvant Chemo in Stage 1B NSCLC
(Posted: 10/30/2008) - The paclitaxel-plus-carboplatin adjuvant chemotherapy regimen offers no survival benefit to patients with stage 1B non-small-cell lung cancer, according to a report published online September 22, 2008, in the Journal of Clinical Oncology.
3. Cetuximab Plus Chemotherapy Extends Survival for Advanced Lung Cancer
(Posted: 06/19/2008) - Patients with advanced non-small-cell lung cancer who received cetuximab (Erbitux) plus chemotherapy lived on average five weeks longer than patients who received chemotherapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
4. Radiotherapy Can Prevent Spread of Small-Cell Lung Cancer to the Brain
(Posted: 06/20/2007, Reviewed: 08/21/2007) - Radiation therapy to the head, given to patients who had responded to chemotherapy for advanced small-cell lung cancer, reduced by about two-thirds the risk that patients' tumors would spread to the brain, according to findings presented at the 2007 ASCO meeting in Chicago.
5. Meta-Analysis Suggests Cisplatin Superior to Carboplatin for Advanced NSCLC
(Posted: 06/19/2007) - Cisplatin is likely a better option than carboplatin for patients with advanced-stage non-small-cell lung cancer (NSCLC), according to a meta-analysis in the June 6, 2007, Journal of the National Cancer Institute.
1 2 3 4 Next >
|
|
|
